186 related articles for article (PubMed ID: 30732550)
1. Physiologic MR imaging of the tumor microenvironment revealed switching of metabolic phenotype upon recurrence of glioblastoma in humans.
Stadlbauer A; Oberndorfer S; Zimmermann M; Renner B; Buchfelder M; Heinz G; Doerfler A; Kleindienst A; Roessler K
J Cereb Blood Flow Metab; 2020 Mar; 40(3):528-538. PubMed ID: 30732550
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral heterogeneity of oxygen metabolism and neovascularization uncovers 2 survival-relevant subgroups of IDH1 wild-type glioblastoma.
Stadlbauer A; Zimmermann M; Doerfler A; Oberndorfer S; Buchfelder M; Coras R; Kitzwögerer M; Roessler K
Neuro Oncol; 2018 Oct; 20(11):1536-1546. PubMed ID: 29718366
[TBL] [Abstract][Full Text] [Related]
3. Predicting Glioblastoma Response to Bevacizumab Through MRI Biomarkers of the Tumor Microenvironment.
Stadlbauer A; Roessler K; Zimmermann M; Buchfelder M; Kleindienst A; Doerfler A; Heinz G; Oberndorfer S
Mol Imaging Biol; 2019 Aug; 21(4):747-757. PubMed ID: 30361791
[TBL] [Abstract][Full Text] [Related]
4. Vascular architecture mapping for early detection of glioblastoma recurrence.
Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
[TBL] [Abstract][Full Text] [Related]
5. Physiological MRI Biomarkers in the Differentiation Between Glioblastomas and Solitary Brain Metastases.
Heynold E; Zimmermann M; Hore N; Buchfelder M; Doerfler A; Stadlbauer A; Kremenevski N
Mol Imaging Biol; 2021 Oct; 23(5):787-795. PubMed ID: 33891264
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of glioblastoma is associated with elevated microvascular transit time heterogeneity and increased hypoxia.
Stadlbauer A; Mouridsen K; Doerfler A; Bo Hansen M; Oberndorfer S; Zimmermann M; Buchfelder M; Heinz G; Roessler K
J Cereb Blood Flow Metab; 2018 Mar; 38(3):422-432. PubMed ID: 28273720
[TBL] [Abstract][Full Text] [Related]
7. Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans.
Stadlbauer A; Kinfe TM; Eyüpoglu I; Zimmermann M; Kitzwögerer M; Podar K; Buchfelder M; Heinz G; Oberndorfer S; Marhold F
Clin Cancer Res; 2021 Mar; 27(6):1641-1649. PubMed ID: 33293375
[TBL] [Abstract][Full Text] [Related]
8. Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma.
Bonekamp D; Mouridsen K; Radbruch A; Kurz FT; Eidel O; Wick A; Schlemmer HP; Wick W; Bendszus M; Østergaard L; Kickingereder P
J Cereb Blood Flow Metab; 2017 Feb; 37(2):485-494. PubMed ID: 26861817
[TBL] [Abstract][Full Text] [Related]
9. Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results.
Stadlbauer A; Zimmermann M; Bennani-Baiti B; Helbich TH; Baltzer P; Clauser P; Kapetas P; Bago-Horvath Z; Pinker K
Mol Imaging Biol; 2019 Aug; 21(4):758-770. PubMed ID: 30478507
[TBL] [Abstract][Full Text] [Related]
10. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
[TBL] [Abstract][Full Text] [Related]
11. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
12. The angiogenic switch leads to a metabolic shift in human glioblastoma.
Talasila KM; Røsland GV; Hagland HR; Eskilsson E; Flønes IH; Fritah S; Azuaje F; Atai N; Harter PN; Mittelbronn M; Andersen M; Joseph JV; Hossain JA; Vallar L; Noorden CJ; Niclou SP; Thorsen F; Tronstad KJ; Tzoulis C; Bjerkvig R; Miletic H
Neuro Oncol; 2017 Mar; 19(3):383-393. PubMed ID: 27591677
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of Recurrent Glioblastoma from Delayed Radiation Necrosis by Using Voxel-based Multiparametric Analysis of MR Imaging Data.
Yoon RG; Kim HS; Koh MJ; Shim WH; Jung SC; Kim SJ; Kim JH
Radiology; 2017 Oct; 285(1):206-213. PubMed ID: 28535120
[TBL] [Abstract][Full Text] [Related]
14. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Tumor Microenvironment Characterization of Contrast Enhancing Brain Tumors Using Physiologic MRI.
Stadlbauer A; Marhold F; Oberndorfer S; Heinz G; Zimmermann M; Buchfelder M; Heynold E; Kinfe TM
Metabolites; 2021 Sep; 11(10):. PubMed ID: 34677383
[TBL] [Abstract][Full Text] [Related]
16. MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Beppu T; Terasaki K; Sasaki T; Sato Y; Tomabechi M; Kato K; Sasaki M; Ogasawara K
Clin Nucl Med; 2016 Nov; 41(11):852-857. PubMed ID: 27648703
[TBL] [Abstract][Full Text] [Related]
17. Relationships between recurrence patterns and subventricular zone involvement or CD133 expression in glioblastoma.
Yamaki T; Shibahra I; Matsuda KI; Kanemura Y; Konta T; Kanamori M; Yamakawa M; Tominaga T; Sonoda Y
J Neurooncol; 2020 Feb; 146(3):489-499. PubMed ID: 32020479
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
19. Dynamic MR imaging for functional vascularization depends on tissue factor signaling in glioblastoma.
Chen X; Xie T; Fang J; Xue W; Kang H; Tong H; Guo Y; Zhang B; Wang S; Yang Y; Zhang W
Cancer Biol Ther; 2018 May; 19(5):416-426. PubMed ID: 29333924
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
Tini P; Nardone V; Pastina P; Battaglia G; Miracco C; Carbone SF; Sebaste L; Rubino G; Cerase A; Pirtoli L
World Neurosurg; 2018 Jan; 109():e662-e668. PubMed ID: 29061455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
